Combined Therapy of Methylprednisolone and Brain-Derived Neurotrophic Factor Promotes Axonal Regeneration and Functional Recovery after Spinal Cord Injury in Rats.

LX Li,QW Xu,YZ Wu,WX Hu,PJ Gu,Z Fu
2003-01-01
Abstract:Objective To investigate the effects of combination therapy with methylprednisolone ( MP) and brain-derived neurotrophic factor (BDNF) on axonal remyelination and functional recovery after spinal cord injury in rats.Methods Forty-five rats were randomly divided into three groups: Group A received MP and BDNF; group B received MP and cerebrospinal fluid (CSF); and group C received CSF only. Contusion injury to adult rat spinal cord was produced at the T-10 vertebra level followed by immediate intravenous MP or CSF, and was thereafter infused intrathecally with BDNF or CSF for 6 weeks. Axonal remyelination and functional recovery was observed using RT-PCR, immunohistochemistry and open field locomotion.Results An increase of 28.4% +/- 2.3% in the expression of proteolipid protein ( PLP) gene, an endogenous indicator of axonal remyelination, was demonstrated in group A 24 hours after injury. Ten weeks later, there were significant decreases in hematogenous inflammatory cellular infiltration in groups A and B compared to C ( P < 0.05). Concomitantly, a significant amount of axonal remyelination was observed in group A compared to groups B and C ( P < 0.05). Furthermore, combination therapy using MP and BDNF in group A resulted in stimulation of hindlimb activity as well as improvement in the rate of functional recovery in open field locomotion ( P < 0.05).Conclusions Combined therapy of MP and BDNF can improve functional recovery through mechanisms that include attenuating inflammatory cellular. infiltration and enhancing axonal remyelination at the injury site. Such a combination may be an effective approach for treatment of spinal cord injury.
What problem does this paper attempt to address?